Highlights Incyte Corporation

Equities

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 05/06/2026 BST			5-day change	1st Jan Change
102.38 ^USD	+1.13%		+5.83%	+3.65%

06-04	Incyte, Mirum Pharmaceuticals to Present New Zilurgisertib Study Results at Conference	MT
06-01	Wall Street Starts June on Edge

Highlights

05-30	Incyte Announces Positive Results from Pivotal Phase 3 Frontmind Trial Evaluating Tafasitamab (Monjuvi/Minjuvi) and Lenalidomide Added to R-Chop Versus R-Chop Alone in Previously Untreated High-Risk Dlbcl and Hgbl	CI
05-20	Incyte, Genesis Molecular AI Expand Artificial Intelligence Drug Discovery Agreement	MT
05-19	Incyte Collaborates With Edison Scientific to Use AI in Drug Discovery	MT
05-19	Incyte and Edison Scientific Enters Strategic Collaboration to Employ Kosmos AI Platform for Research and Development	CI
05-07	Incyte Announces 24-Week Data For Opzelura Cream In Adults With Moderate Atopic Dermatitis	CI
05-01	Incyte Announces Fda Approval of Jakafi Xr Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease	CI
04-28	Incyte beats first-quarter estimates on strong demand for cancer drugs	RE
04-28	Incyte Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-28	Incyte's Q1 Non-GAAP Earnings, Revenue Increase	MT
04-28	Earnings Flash (INCY) Incyte Corporation Posts Q1 Adjusted EPS $1.81 per Share, vs. FactSet Est of $1.32	MT
04-28	Earnings Flash (INCY) Incyte Corporation Reports Q1 Revenue $1.27B, vs. FactSet Est of $1.22B	MT
04-28	Incyte Corporation Reaffirms Earnings Guidance for the Fiscal Year 2026	CI
04-21	Incyte Highlights New Phase 3 Tafasitamab Data At the 2026 American Society of Clinical Oncology Annual Meeting	CI
03-28	Incyte Announces New Positive 54-Week Data for Povorcitinib in Hidradenitis Suppurativa	CI
03-28	Incyte's skin disease drug shows long-term symptom relief in late-stage trials	RE
03-25	Incyte announces executive leadership appointments	RE
03-24	Karyopharm's drug meets one of two goals in blood cancer trial	RE
03-20	Incyte Highlights Late-Breaking Hidradenitis Suppurativa Data And Features Ruxolitinib Cream And Povorcitinib At The American Academy Of Dermatology Annual Meeting	CI
03-06	Incyte Corporation Receives Complete Response Letter From FDA For Zynyz Supplemental Biologics License Application	CI
03-06	Incyte announces the European Commission approval of Zynyz® (retifanlimab) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC)	RE
03-06	Incyte Announces European Commission Approval of Zynyz (Retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal	CI
02-13	Incyte's weak Opzelura 2026 revenue forecast heightens Jakafi patent concerns (Feb 10)	RE
02-10	Incyte Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-10	Incyte Q4 Adjusted Earnings, Revenue Rise; Shares Down Pre-Bell	MT
02-10	Incyte Corporation Provides Earnings Guidance for the Fiscal Year 2026	CI